CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids

Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919

Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem Pharmacol, 50, 83, 10.1016/0006-2952(95)00109-D

Sugiura, 1995, 2-Arachidonylglycerol—a possible endogenous cannabinoid receptor ligand in the brain, Biochem Biophys Res Commun, 215, 89, 10.1006/bbrc.1995.2437

Hanus, 2001, 2-arachidonyl glyceryl ether, an endognous agonist of the cannabinoid CB1 receptor, Proc Natl Acad Sci USA, 98, 3662, 10.1073/pnas.061029898

Matsuda, 1990, Structure of cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561, 10.1038/346561a0

Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61, 10.1038/365061a0

Breivogel, 2001, Evidence for a new G-protein coupled cannabinoid receptor in mouse brain, Mol Pharmacol, 60, 155, 10.1124/mol.60.1.155

Glass, M. McAllister, S. D. Cannabinoid mediated signal transduction, Onaivi, E, The biology of marijuana: from gene to behaviour, Harwood Academic, Reading

Felder, 1995, Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors, Mol Pharmacol, 48, 443

Pertwee, 1997, Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol Ther, 74, 129, 10.1016/S0163-7258(97)82001-3

Deadwyler, 1995, Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP dependent process, J Pharmacol Exp Ther, 273, 734

McAllister, 1999, Cannabiniod receptors can activate and inhibit G-protein coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system, J Pharmacol Exp Ther, 291, 618

Glass, 1999, Agonist selective regulation of G-proteins by cannabinoid CB1 and CB2 receptors, Mol Pharmacol, 56, 1362, 10.1124/mol.56.6.1362

Selley, 1996, Cannabinoid receptor stimulation of guanosine-5′-O-(3-[S-35] thio)triphosphate binding in rat brain membranes, Life Sci, 59, 659, 10.1016/0024-3205(96)00347-5

Breivogel, 1997, Regional differences in cannabinoid receptor G-protein coupling in rat brain, J Pharmacol Exp Ther, 282, 1632

Griffin, 1998, Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5′-O-2[35guanosine-5′-O-2[35S]thio)-triphosphate binding assay in rat cerebellar membranes, J Pharmacol Exp Ther, 285, 553

Kearn, 1999, Relationship between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange, J Neurochem, 72, 2379, 10.1046/j.1471-4159.1999.0722379.x

Breivogel, 1998, Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity, J Biol Chem, 273, 16865, 10.1074/jbc.273.27.16865

Burkey, 1997, Relative efficacies of cannabinoid CB1> receptor agonists in the mouse brain, Eur J Pharmacol, 336, 295, 10.1016/S0014-2999(97)01255-7

Glass, M. Northup, J. K. Differential activation of G-proteins by endocannabinoids

Felder, 1993, Anandamide, an endogenous cannabimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor mediated signal transduction, Proc Natl Acad Sci USA, 90, 7656, 10.1073/pnas.90.16.7656

Stella, 1997, A second endogenous cannabinoid that modulates long-term potentiation, Nature, 388, 773, 10.1038/42015

Gonsiorek, 2000, Endocannabiniod 2-arachidonyl-glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide, Mol Pharmacol, 57, 1045

Sugiura, 2000, Evidence that 2-arachidonolyglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor, J Biol Chem, 275, 605, 10.1074/jbc.275.1.605

Maneuf, 1996, Activation of the cannabinoid receptor by delta-9-tetrahydrocannabinol reduces GABA uptake in the globus pallidus, Eur J Pharmacol, 308, 161, 10.1016/0014-2999(96)00326-3

Glass, 1997, Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs-linkage to the CB1 receptor, J Neurosci, 17, 5327, 10.1523/JNEUROSCI.17-14-05327.1997

Bonhaus, 1998, Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist specific trafficking of intracellular responses, J Pharmacol Exp Ther, 287, 884

Caulfield, 1992, Cannabinoid receptor agonists inhibit CA current in N9108-15 neuroblastoma cells via a pertussis toxin sensitive mechanism, Br J Pharmacol, 106, 231, 10.1111/j.1476-5381.1992.tb14321.x

Mackie, 1993, Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells, Mol Pharmacol, 44, 498

Gudermann, 1997, Functional and structural complexity of signal transduction via G-protein coupled receptors, Annu Rev Neurosci, 20, 399, 10.1146/annurev.neuro.20.1.399

Mackie, 1995, Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in ATT20 cells transfected with rat brain cannabinoid receptors, J Neurosci, 15, 6552, 10.1523/JNEUROSCI.15-10-06552.1995

Gifford, 1996, Electrically-evoked acetylcholine-release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR141716A, J Pharmacol Exp Ther, 277, 1431

Shen, 1996, Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures, J Neurosci, 16, 4322, 10.1523/JNEUROSCI.16-14-04322.1996

Gessa, 1997, Inhibition of hippocampal acetylcholine release by cannabinoids—reversal by SR141716A, Eur J Pharmacol, 327, R1, 10.1016/S0014-2999(97)89683-5

Kathmann, 1999, Cannabinoid CB1 receptor-mediated inhibition of NMDA and kainate-stimulated noradrenaline and dopamine release in the brain, Naunyn Schmiedeberg's Arch Pharmacol, 359, 466, 10.1007/PL00005377

Katona, 1999, Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons, J Neurosci, 19, 4544, 10.1523/JNEUROSCI.19-11-04544.1999

Terranova, 1995, Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55,212-2—reversal by SR141716, a selective antagonist of CB1 cannabinoid receptors, Naunyn Schmiedeberg's Arch Pharmacol, 352, 576, 10.1007/BF00169393

Misner, 1999, Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons, J Neurosci, 19, 6795, 10.1523/JNEUROSCI.19-16-06795.1999

Di Marzo, 1994, Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature, 372, 686, 10.1038/372686a0

Egertová, 1998, A new perspective on cannabinoid signalling: complementary localisation of fatty acid amide hydrolase and the CB1 receptor in rat brain, Proc R Soc London, 265, 2081, 10.1098/rspb.1998.0543

Elphick, 2001, The neurobiology and evolution of cannabinoid signalling, Philos Trans R Soc London [Biol], 356, 381, 10.1098/rstb.2000.0787

Christie, 2001, Cannabinoids act backwards, Nature, 410, 527, 10.1038/35069167

Sánchez, 1998, delta-9-tetrahydrocannabinol induces apoptosis in C6 glioma cells, FEBS Lett, 436, 6, 10.1016/S0014-5793(98)01085-0

Ohno-Shosaku, 2001, Endogenous cannabinoids mediate retrograde signals from depolarised postsynaptic terminals, Neuron, 29, 729, 10.1016/S0896-6273(01)00247-1

Wilson, 2001, Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses, Nature, 410, 588, 10.1038/35069076

Kreitzer, 2001, Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells, Neuron, 29, 717, 10.1016/S0896-6273(01)00246-X

Cravatt, 1996, Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, Nature, 384, 83, 10.1038/384083a0

Giuffrida, 2001, Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology, J Pharmacol Exp Ther, 298, 7

Gebremedhin, 1999, Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current, Am J Physiol, 276, h2085

Straiker, 1999, Cannabinoid CB1 receptors and ligands in vertebrate retina: localisation and function of an endogenous signalling system, Proc Natl Acad Sci USA, 96, 14565, 10.1073/pnas.96.25.14565

Hampson, 1998, Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission, J Neurochem, 70, 671, 10.1046/j.1471-4159.1998.70020671.x

Netzeband, 1999, Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture, J Neurosci, 19, 8765, 10.1523/JNEUROSCI.19-20-08765.1999

Miller, 1992, Potentiation of NMDA receptor currents by arachidonic acid, Nature, 355, 722, 10.1038/355722a0

Robbe, 2001, Localisation and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens, J Neurosci, 21, 109, 10.1523/JNEUROSCI.21-01-00109.2001

Maingret, 2001, The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1, EMBO J, 20, 47, 10.1093/emboj/20.1.47

Lesage, 2000, Molcular and functional properties of two-pore-domain potassium channels, Am J Physiol, 279, F793

Sirois, 2000, The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics, J Neurosci, 20, 6347, 10.1523/JNEUROSCI.20-17-06347.2000

Schweitzer, 2000, Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons, J Neurosci, 20, 51, 10.1523/JNEUROSCI.20-01-00051.2000

Reichman, 1991, Delta-9-tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices, Mol Pharmacol, 40, 547

Mombouli, 1999, Anandamide induced mogilization of cytosolic Ca2+ in endothelial cells, Br J Pharmacol, 126, 1593, 10.1038/sj.bjp.0702483

Sugiura, 1997, Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering Ca2+ transient in NG108-15 cells, J Biochem, 122, 890, 10.1093/oxfordjournals.jbchem.a021838

Sugiura, 1997, Inhibition by 2-arachidonyl glycerol, a novel type of possible neuromodulator, or the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells, Biochem Biophys Res Commun, 233, 207, 10.1006/bbrc.1997.6425

Sugiura, 1996, 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells, Biochem Biophys Res Commun, 229, 58, 10.1006/bbrc.1996.1757

Sugiura, 1999, Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor, J Biol Chem, 274, 2794, 10.1074/jbc.274.5.2794

Jin, 1994, Opioids mobilize calcium from inositol 1,4,5-triphosphate-sensitive stores in NG108-15 cells, J Neurosci, 14, 1920, 10.1523/JNEUROSCI.14-04-01920.1994

Slipetz, 1995, Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase, Mol Pharmacol, 48, 352

Guzmán, 2001, Control of cell survival/death decision by cannabinoids, J Mol Med, 78, 613, 10.1007/s001090000177

Bouaboula, 1995, Activation of mitogen-activated protein–kianase by stimulation of the central cannabinoid receptor CB1, Biochem J, 312, 637, 10.1042/bj3120637

Bouaboula, 1996, Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor - Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression, Eur J Biochem, 237, 704, 10.1111/j.1432-1033.1996.0704p.x

Wartmann, 1995, The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide, FEBS Lett, 359, 133, 10.1016/0014-5793(95)00027-7

Liu, 2000, Functional CB1 cannabinoid receptors in human vascular endothelial cells, Biochem J, 346, 835, 10.1042/0264-6021:3460835

Bouaboula, 1999, Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways, FEBS Lett, 449, 61, 10.1016/S0014-5793(99)00395-6

Bouaboula, 1995, Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells, J Biol Chem, 270, 13973, 10.1074/jbc.270.23.13973

Glass, 1995, Selective induction of Krox 24 in striosomes by a cannabinoid agonist, NeuroReport, 6, 241, 10.1097/00001756-199501000-00004

Porcella, 1998, Delta(9)-tetrahydrocannibinol increases sequence-specific AP-1 binding activity and Fos-related antigens in the rat brain, Eur J Neurosci, 10, 1743, 10.1046/j.1460-9568.1998.00175.x

Mailleux, 1994, Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain, NeuroReport, 5, 1265, 10.1097/00001756-199406020-00028

Bouaboula, 1997, A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions, J Biol Chem, 272, 22330, 10.1074/jbc.272.35.22330

Gómez del Pulgar, 2000, The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt, Biochem J, 347, 369, 10.1042/0264-6021:3470369

Rueda, 2000, The CB1 cannabinoid receptor is coupled to the activation of cJUN N-terminal kinase, Mol Pharmacol, 58, 814, 10.1124/mol.58.4.814

Derkinderen, 2001, Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus, J Neurochem, 77, 957, 10.1046/j.1471-4159.2001.00333.x

Minden, 1998, The JNK family of MAP kinases: regulation and function, Horm Signal, 1, 209, 10.1016/B978-012312411-1/50008-1

Saleshando, 2000, SB203580, the p38 mitogen-activated protein kinase inhibitor blcoks the inhibitiory effect of beta-amyloid on long-term potentiation in the rat hippocampus, Neurosci Lett, 288, 119, 10.1016/S0304-3940(00)01210-6

Landsman, 1998, AM630 is an inverse agonist at the human cannabinoid CB1 receptor, Life Sci, 62, PL109, 10.1016/S0024-3205(97)01187-9

Galve-Roperh, 2000, Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation, Nat Med, 6, 313, 10.1038/73171

Kolesnick, 1998, Regulation of ceramide production and apoptosis, Annu Rev Physiol, 60, 643, 10.1146/annurev.physiol.60.1.643

Sánchez, 1998, Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the delta-9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes, Mol Pharmacol, 54, 834, 10.1124/mol.54.5.834

Sánchez, 2001, The CB1 cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan, Mol Pharmacol, 59, 955, 10.1124/mol.59.5.955

De Petrocellis, 1998, The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation, Proc Natl Acad Sci USA, 95, 8375, 10.1073/pnas.95.14.8375

Melck, 2000, Supression of nerve growth factor trk receptors and prolactin receptors by endocannabinoid leads to inhibition of human breast and prostate cancer cell proliferation, Endocrinology, 141, 118, 10.1210/endo.141.1.7239

Melck, 1999, Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells, FEBS Lett, 463, 235, 10.1016/S0014-5793(99)01639-7

Sarker, 2000, Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3, FEBS Lett, 472, 39, 10.1016/S0014-5793(00)01425-3

Zygmunt, 1999, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature, 400, 452, 10.1038/22761

Maccarrone, 2000, Anandamide induces apoptosis in human cells via vanilloid receptors, J Biol Chem, 275, 31938, 10.1074/jbc.M005722200

Tang, 1993, Delta-9-tetrahydrocannabinoil-(THC)-mediated inhibition of macrophage macromolecular metabolism is antagonized by human serum -proteins and by cell surface proteins, Int J Immunopharm, 15, 665, 10.1016/0192-0561(93)90139-P

Burnette-Curley, 1993, delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of bacillus calmette-guerin-activated macrophages, Int J Immunopharm, 15, 371, 10.1016/0192-0561(93)90048-4

Pestonjamasp, 1998, Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system, Biochem Biophys Acta, 1394, 249, 10.1016/S0005-2760(98)00110-6

DiMarzo, 1996, Biosynthesis of anandamide and related acylamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells, Biochem J, 316, 977, 10.1042/bj3160977

Varga, 1998, Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension, FASEB J, 12, 1035, 10.1096/fasebj.12.11.1035

DiMarzo, 1999, Biosynthesis and inactivation of the endocannabinoid 2-arachidonylglycerol in circulating and tumoural macrophages, Eur J Biochem, 264, 258, 10.1046/j.1432-1327.1999.00631.x

Kozak, 2000, Oxygenation of the endocannabinoid, 2-arachidonyl gylcerol, to glyceryl prostaglandins by cyclooxygenase-2, J Biol Chem, 275, 33744, 10.1074/jbc.M007088200

Galiegue, 1995, Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations, Eur J Biochem, 232, 54, 10.1111/j.1432-1033.1995.tb20780.x

Bouaboula, 1993, Cannabinoid receptor expression in human leukocytes, Eur J Biochem, 214, 173, 10.1111/j.1432-1033.1993.tb17910.x

Jeon, 1996, Attenuation of inducible nitric oxide synthase gene-expression by delta(9)-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa-B/Rel activation, Mol Pharmacol, 50, 334

Chang, 2001, Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids, J Cell Biochem, 81, 715, 10.1002/jcb.1103

Coffey, 1996, Tetrahydro- cannabinol inhibition of macrophage nitric-oxide production, Biochem Pharmacol, 52, 743, 10.1016/0006-2952(96)00356-5

Derocq, 2000, Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60, J Biol Chem, 275, 15621, 10.1074/jbc.275.21.15621

Hillard, 2000, Endocannabinoids and vascular function, J Pharmacol Exp Ther, 294, 27

Varga, 1995, Novel antangonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide, Eur J Pharmacol, 278, 279, 10.1016/0014-2999(95)00181-J

Ishac, 1996, Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves, Br J Pharmacol, 118, 2023, 10.1111/j.1476-5381.1996.tb15639.x

Wagner, 1999, Mesenteric vasodilation mediated by endothialial anandamide receptors, Hypertension, 33, 429, 10.1161/01.HYP.33.1.429

Jàrai, 1999, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors, Proc Natl Acad Sci USA, 96, 14136, 10.1073/pnas.96.24.14136

Macho, 1999, Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium, Cell Death Differ, 6, 155, 10.1038/sj.cdd.4400465

Chaytor, 1999, The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication, J Physiol, 520, 539, 10.1111/j.1469-7793.1999.00539.x

Calignano, 1998, Control of pain initiation by endogenous cannabinoids, Nature, 394, 277, 10.1038/28393

Baker, 2000, Cannabinoids control spasticity and tremor in a multiple sclerosis model, Nature, 404, 84, 10.1038/35003583

Showalter, 1996, Evaluation of binding in a transfected cell-line expressing a peripheral cannabinoid receptor (CB2)—identification of cannabinoid receptor subtype-selective ligands, J Pharmacol Exp Ther, 278, 989

Moody, 2001, Selective oxygenation of endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase, Biochemistry, 40, 861, 10.1021/bi002303b

Yu, 1997, Synthesis of prostaglandin E2-ethanolamide from anandamide by cyclooxygenase-2, J Biol Chem, 272, 21181, 10.1074/jbc.272.34.21181